Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference

August 2, 2018

BOTHELL, Wash., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Robert W. Azelby, Alder’s president and chief executive officer, at the Canaccord Genuity 38th Annual Growth Conference at 2:30 p.m. ET on Thursday, August 9, 2018 in Boston, MA.

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for at least 30 days after the live event concludes.

-- Link:http://wsw.com/webcast/canaccord30/aldr/

About Alder BioPharmaceuticals, Inc.Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit www.alderbio.com.

Investor Relations Contacts:Ashwin AgarwalVice President, Corporate StrategyAlder Biopharmaceuticals, Inc.425-408-8567 aagarwal@alderbio.com

Michael SchaffzinStern Investor Relations, Inc.212-362-1200 michael@sternir.com

Media Contact: Ashley Cadle TogoRun a.cadle@togorun.com 310.463.0143

Update hourly